FORMULATIONS FOR MEDIATING INFLAMMATORY BOWEL DISORDERS

• US 20070173480A1
• Filed: 01/12/2007
• Published: 07/26/2007
• Est. Priority Date: 03/12/2004
• Status: Active Grant

• Current Assignee: MTI Meta Tech, Inc.
• Original Assignee: MTI Meta Tech, Inc.
• Inventors: CLANDININ, Michael, PARK, Eek
• Granted Patent: US 7,851,451 B2
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 47/28 Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.

Claims

1. A formulation comprising at least one ganglioside in combination with an acceptable excipient for mediating an inflammatory bowel disorder.

2. The formulation according to claim 1 wherein mediating comprises preventing or treating an inflammatory bowel disorder.

3. The formulation according to claim 1 wherein the inflammatory bowel disorder is necrotizing enterocolitis.

4. The formulation according to claim 1, wherein said ganglioside is selected from the group consisting of:

GD3, GM1, GM2, GM3, and GD1b.

5. The formulation according to claim 1 in the form of a supplemented liquid or food.

6. The formulation according to claim 5, wherein said supplemented liquid or food comprises an infant formula or infant food.

7. The formulation of claim 1 wherein the at least one ganglioside comprises about 80% GD3, 9% GD1b, and 5% GM3 on a weight/weight basis.

8. The formulation of claim 1 wherein one ganglioside selected from the group consisting of GD3, GM1, GM2, GM3, and GD1b, comprises more than 50% of ganglioside content.

9. A method for mediating an inflammatory bowel disorder in a subject in need thereof comprising the step of administering at least one ganglioside to said subject.

10. The method of claim 9 wherein administering comprises oral consumption.

11. The method according to claim 9 wherein mediating comprises preventing or treating an inflammatory bowel disorder.

12. The method according to claim 9 wherein said inflammatory bowel disorder is necrotizing enterocolitis.

13. The method according to claim 9, wherein said ganglioside is selected from the group consisting of:

GD3, GM1, GM2, GM3, and GD1b.

14. The method of claim 10 wherein oral consumption comprises consumption of a ganglioside supplemented liquid or food.

15. The method of claim 14 wherein said supplemented liquid or food comprises an infant formula or infant food.

16. A method for reducing blood cholesterol in a subject in need thereof comprising the step of providing at least one ganglioside to said subject for oral consumption.

17. The method according to claim 16, wherein said ganglioside is selected from the group consisting of:

GD3, GM1, GM2, GM3, and GD1b.